Skip to Content
Authors Geraghty PJ, Matsumura JS, Conte MS
Author Profile(s)
Journal J. Vasc. Surg. Volume: 50 Issue: 6 Pages: 1459-61
Publish Date 2009 Dec
PubMed ID 19897333

Medical devices are cleared for marketing approval through the Food and Drug Administration (FDA). Unique statutory requirements, such as the “least burdensome mandate,” have allowed the FDA to employ non-concurrent controls in its evaluation of prospective therapies. The use of Objective Performance Criteria and Goals (OPC and OPG) for the premarket evaluation of cardiovascular devices has become established as an alternative to randomized, controlled trials (RCTs). These single-armed comparisons may facilitate rapid entry of novel devices to the market. Unlike RCTs, they do not establish superiority or non-inferiority of the examined therapy, and study populations must be carefully inspected to ensure validity of comparisons to historical controls. Copyright © 2016 The Board of Regents of the University of Wisconsin System